The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations

V. Russell, A. Connolly, J. Dlugozima, P. Woodman, A. Young (Stoke Poges, United Kingdom)

Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Session: Preclinical models for the development of new drugs for respiratory diseases
Session type: Thematic Poster Session
Number: 672
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Russell, A. Connolly, J. Dlugozima, P. Woodman, A. Young (Stoke Poges, United Kingdom). The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations. Eur Respir J 2013; 42: Suppl. 57, 672

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Comparing the effects of orally and intranasally administered IKK2 inhibitors in a 4 day tobacco-smoke exposed model of COPD
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013

The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016

The effects of clinically relevant reference agents in a mouse model of severe asthma
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015


Polyphenolic compounds and experimentally induced allergic asthma
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013

CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

Efficacy of dexamethasone, roflumilast and azithromycin in a murine cigarette smoke/NTHi infection model
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016

Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation
Source: International Congress 2016 – Airway response to infection
Year: 2016


Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014


An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013

Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013

In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014


Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


Nicotine impairs inflammation-induced airway relaxation in a in vitro murine model of asthma
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013


Antioxidant effects of bisphosphonates in smoking- induced lung injury in rat model
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015